Product image of Linagliptine Aurobindo (Linagliptin) supplied by GNH India

Linagliptine Aurobindo

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptine Aurobindo (Linagliptin)

Linagliptin, the active ingredient in Linagliptine Aurobindo, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients.

GNH India supplies Linagliptine Aurobindo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aurobindo Pharma B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptine Aurobindo is a DPP-4 inhibitor indicated for the management of type 2 diabetes mellitus and related therapeutic pathways.

  • Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels.
  • Combination therapy with other antidiabetic agents: enhances overall glucose lowering when added to metformin, sulfonylureas, or insulin.
  • Adjunct to diet and exercise: supports blood sugar management as part of a comprehensive lifestyle plan.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, endogenous incretin levels rise, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby reducing blood glucose concentrations.

Side Effects

Linagliptine Aurobindo may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nasal passages and throat.
  • Headache: transient cranial discomfort.
  • Upper respiratory tract infection: symptoms such as cough and sore throat.
  • Dizziness: occasional light‑headed sensation.
  • Gastrointestinal discomfort: mild nausea or abdominal pain.
  • Back pain: occasional musculoskeletal ache.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain, nausea, and vomiting requiring immediate medical attention.
  • Severe allergic reactions: including angioedema, Stevens‑Johnson syndrome, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: rare skin blistering disorder.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.

Precautions & Warnings

Before initiating Linagliptine Aurobindo, clinicians should consider several safety aspects.

  • Renal impairment: assess kidney function and follow prescriber guidance for dose adjustment.
  • Hepatic impairment: monitor liver enzymes regularly.
  • Risk of hypoglycemia: heightened when used with insulin or sulfonylureas; educate patients on signs.
  • Pancreatitis: discontinue if persistent abdominal pain or elevated pancreatic enzymes occur.
  • Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk.
  • Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Avoid Interactions

Linagliptine Aurobindo can interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid)

  • Concomitant insulin or sulfonylureas: may cause significant hypoglycemia.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure and efficacy.

Moderate Interactions (Monitor Closely):\n- Diuretics: may affect glucose control; monitor blood glucose.

  • ACE inhibitors or ARBs: observe blood pressure and renal function.
  • Warfarin: periodic INR checks recommended.

Frequently Asked Questions

Linagliptine Aurobindo contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It is used to improve glycaemic control when diet, exercise, and other antidiabetic agents are insufficient.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, preventing the breakdown of incretin hormones GLP‑1 and GIP. Higher incretin levels stimulate insulin release and suppress glucagon, leading to lower blood glucose levels in a glucose‑dependent manner.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions precisely.

Safety data for linagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with sulfonylureas, linagliptin has a lower risk of hypoglycaemia because its glucose‑dependent mechanism requires elevated blood glucose to act. Unlike metformin, it does not affect gastrointestinal absorption and is safe in patients with moderate renal impairment without dose adjustment.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Linagliptine Aurobindo is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush or chew the tablet unless directed by a healthcare professional.

Serious adverse events include pancreatitis, severe allergic reactions such as angioedema or Stevens‑Johnson syndrome, and rare cases of bullous pemphigoid. When combined with insulin or sulfonylureas, there is an increased risk of severe hypoglycaemia.

Patients with a known hypersensitivity to linagliptin or any component of the formulation should avoid the product. Caution is also advised for individuals with severe hepatic disease, and it is contraindicated in those with a history of pancreatitis until cleared by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT